![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 22, 2015 10:18:14 AM
LTG, we know you are not in healthcare, but how does a value analysis committee approve Alf/Transenterix when it is the same cost of davinci and same technology (or a step back in technology)? It is not going to happen
Also, how will TRXC now manufacture two completely different end effectors?
IMO, TRXC and Laviollette made a play for Titan (b/c they knew Surgibot was not going to be well rec'd by market). Titan rejected the offer and also put a shareholder rights plan in place to protect themselves. TRXC was now stuck and had to go with a plan B which was buying ALF.
Will be curious to see what happens to the stock price of TRXC.
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM